Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina

References

• Abdizadeh R, Hadizadeh F, Abdizadeh T. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2. Mol Divers. 2022;26(2):1–15.
   PubMed Web of Science ®Google Scholar
• Adel A, Elnaggar MS, Albohy A, et al. Evaluation of antiviral activity of carica papaya leaves against SARS-CoV-2 assisted by metabolomic profiling. RSC Adv. 2022;12(51):32844–32852.
   PubMed Web of Science ®Google Scholar
• Adem Ş, Eyupoglu V, Ibrahim IM, et al. Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (mpro) inhibitors to unveil a hope against COVID-19. Comput Biol Med. 2022;145:105452.
   PubMed Web of Science ®Google Scholar
• Agrawal PK, Agrawal C, Blunden G. Pharmacological significance of hesperidin and hesperetin, two citrus flavonoids, as promising antiviral compounds for prophylaxis against and combating COVID-19. Nat Prod Commun. 2021;16(10):1934578X2110425.
   Web of Science ®Google Scholar
• Aini NS, Kharisma VD, Widyananda MH, et al. Bioactive compounds from purslane (portulaca oleracea L.) and star anise (illicium verum hook) as SARS-CoV-2 antiviral agent via dual inhibitor mechanism: in silico approach. Pharmacogn J. 2022;14(4):352–357.
   Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, et al. Ginkgo biloba in the management of the COVID-19 severity. Arch Pharm (Weinheim). 2022;355(10):e2200188.
   PubMed Web of Science ®Google Scholar
• Altu NS, Budiman C, Razali R, et al. Technical data of In silico analysis of the interaction of dietary flavonoid compounds against spike-glycoprotein and proteases of SARS-CoV-2. Data. 2022;7(11):144.
   Web of Science ®Google Scholar
• Amin SA, Banerjee S, Ghosh K, et al. Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (mpro) and papain-like protease (PLpro) inhibitors. Bioorg Med Chem. 2021;29:115860.
   PubMedGoogle Scholar
• Aranda J, Wieczór M, Terrazas M, et al. Mechanism of reaction of RNA-dependent RNA polymerase from SARS-CoV-2. Chem Catal. 2022;2(5):1084–1099.
   PubMedGoogle Scholar
• Bachar SC, Mazumder K, Bachar R, et al. A review of medicinal plants with antiviral activity available in Bangladesh and mechanistic insight into their bioactive metabolites on SARS-CoV-2, HIV and HBV. Front Pharmacol. 2021;12:732891.
   PubMed Web of Science ®Google Scholar
• Basu A, Sarkar A, Maulik U. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Sci Rep. 2020;10(1):17699.
   PubMed Web of Science ®Google Scholar
• Begum F, Srivastava AK, Ray U. Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): in silico-molecular insight. Biochem Biophys Res Commun. 2021;571:26–31.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369(6511):1586–1592.
   PubMed Web of Science ®Google Scholar
• Chen TH, Tsai MJ, Chang CS, et al. The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion. J Infect Public Health. 2023;16(1):42–54.
   PubMedGoogle Scholar
• Cho CC, Li SG, Lalonde TJ, et al. Drug repurposing for the SARS-CoV-2 papain-Like protease. ChemMedChem. 2022;17(1):e202100455.
   PubMed Web of Science ®Google Scholar
• Corbo T, Miralem M, Kalajdzic A, et al. In silico prediction of the inhibitory effect of phytochemical components extracted from knautia sarajevensis on the main protease of SARS-CoV-2 virus. GenApp. 2022;6(2):31–40.
   Google Scholar
• Das S, Sarmah S, Lyndem S, et al. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn. 2021;39(9):3347–3357.
   PubMed Web of Science ®Google Scholar
• Farouk AE, Baig MH, Khan MI, et al. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: a viroinformatics study. Saudi J Biol Sci. 2021;28(6):3262–3269.
   PubMed Web of Science ®Google Scholar
• Ferreira JC, Fadl S, Villanueva AJ, et al. Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-chymotrypsin-like protease. Front Chem. 2021;9:692168.
   PubMed Web of Science ®Google Scholar
• Frazier MN, Dillard LB, Krahn JM, et al. Characterization of SARS2 Nsp15 nuclease activity reveals it’s mad about U. Nucleic Acids Res. 2021;49(17):10136–10149.
   PubMed Web of Science ®Google Scholar
• Gasmi A, Mujawdiya PK, Lysiuk R, et al. Quercetin in the prevention and treatment of coronavirus infections: a focus on SARS-CoV-2. Pharmaceuticals (Basel, Switzerland). 2022;15(9):1049.
   PubMedGoogle Scholar
• Hognon C, Marazzi M, García-Iriepa C. Atomistic-level description of the covalent inhibition of SARS-CoV-2 papain-like protease. IJMS. 2022;23(10):5855.
   Google Scholar
• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154.
   PubMed Web of Science ®Google Scholar
• Ibrahim TM, Ismail MI, Bauer MR, et al. Supporting SARS-CoV-2 papain-like protease drug discovery: in silico methods and benchmarking. Front Chem. 2020;8:592289.
   PubMed Web of Science ®Google Scholar
• Jendele L, Krivak R, Skoda P, et al. PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Res. 2019;47(W1):W345–W349.
   PubMed Web of Science ®Google Scholar
• Jiang H, Yang P, Zhang J. Potential inhibitors targeting papain-Like protease of SARS-CoV-2: two birds with one stone. Front Chem. 2022;10:822785.
   PubMed Web of Science ®Google Scholar
• Kaul R, Paul P, Kumar S, et al. Promising antiviral activities of natural flavonoids against SARS-CoV-2 targets: systematic review. IJMS. 2021;22(20):11069.
   Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–D1395.
   PubMed Web of Science ®Google Scholar
• Kim Y, Wower J, Maltseva N, et al. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun Biol. 2021;4(1):193.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kashyap P, Chowdhury S, et al. Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication. Phytomed. 2021;85:153317.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paul P, Yadav P, et al. A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle. Comput Biol Med. 2022;142:105231.
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–2786.
   PubMed Web of Science ®Google Scholar
• Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antiviral Res. 2018;149:58–74.
   PubMed Web of Science ®Google Scholar
• Li D, Luan J, Zhang L. Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors. Biochem Biophys Res Commun. 2021;538:72–79.
   PubMed Web of Science ®Google Scholar
• Liang JJ, Pitsillou E, Ververis K, et al. Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE monte carlo simulations, and in vitro activity inhibition. Chem Phys Lett. 2022;788:139294.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang L, Gao J, et al. Discovery of genistein derivatives as potential SARS-CoV-2 main protease inhibitors by virtual screening, molecular dynamics simulations and ADMET analysis. Front Pharmacol. 2022;13:961154.
   PubMed Web of Science ®Google Scholar
• Ma C, Wang J. Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors. ACS Pharmacol Transl Sci. 2022;5(2):102–109.
   PubMedGoogle Scholar
• Matondo A, Kilembe JT, Ngoyi EM, et al. Oleanolic acid, ursolic acid and apigenin from ocimum basilicum as potential inhibitors of the SARS-CoV-2 main protease: a molecular docking study. IJPR. 2021;6(2):1–16.
   Google Scholar
• Mishra A, Kaur U, Singh A. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study. J Biomol Struct Dyn. 2022;40(11):5128–5137.
   PubMed Web of Science ®Google Scholar
• Moradi M, Golmohammadi R, Najafi A, et al. In silico analysis of inhibiting papain-like protease from SARS-CoV-2 by using plant-derived peptides. Int J Pept Res Ther. 2022;28(1):24.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791.
   PubMed Web of Science ®Google Scholar
• Mouffouk C, Mouffouk S, Mouffouk S, et al. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). Eur J Pharmacol. 2021;891:173759.
   PubMed Web of Science ®Google Scholar
• Munafò F, Donati E, Brindani N, et al. Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. Sci Rep. 2022;12(1):10571.
   PubMed Web of Science ®Google Scholar
• O’Boyle NM, Banck M, James CA, et al. Open babel: an open chemical toolbox. J Cheminform. 2011;3(1):33.
   PubMed Web of Science ®Google Scholar
• Pandey P, Rane JS, Chatterjee A, et al. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. J Biomol Struct Dyn. 2021;39(16):6306–6316.
   PubMed Web of Science ®Google Scholar
• Pendyala B, Patras A. In silico screening of cyanobacterial and food bioactive compounds to predict potential inhibitors of COVID-19 main protease (mpro), papain-like protease (PLpro) and RNA-dependent RNA polymerase (RdRp). ChemRxiv. 2022. This content is a preprint and has not been peer-reviewed.
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF chimera–a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612.
   PubMed Web of Science ®Google Scholar
• Ramesh V, Kulkarni SA, Velusamy P, et al. Current update of phytotherapeutic agents in the treatment of COVID-19: in-silico based virtual screening approach for the development of antiviral drug. Front Biosci (Landmark Ed). 2022;27(4):123.
   PubMed Web of Science ®Google Scholar
• Rehman MFU, Akhter S, Batool AI, et al. Effectiveness of natural antioxidants against SARS-CoV-2? Insights from the in-silico world. Antibiotics (Basel, Switzerland). 2021;10(8):1011.
   PubMed Web of Science ®Google Scholar
• Shahhamzehei N, Abdelfatah S, Efferth T. In silico and in vitro identification of pan-coronaviral main protease inhibitors from a large natural product library. Pharmaceuticals (Basel, Switzerland). 2022;15(3):308.
   PubMedGoogle Scholar
• Singh S, Sk MF, Sonawane A, et al. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis. J Biomol Struct Dyn. 2021;39(16):6249–6264.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Brognaro H, Prabhu PR, et al. Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease. Commun Biol. 2022;5(1):805.
   PubMed Web of Science ®Google Scholar
• Tejera E, Pérez-Castillo Y, Toscano G, et al. Computational modeling predicts potential effects of the herbal infusion "horchata" against COVID-19. Food Chem. 2022;366:130589.
   PubMed Web of Science ®Google Scholar
• The PyMOL Molecular Graphics System. Version 2.5.4. Schrödinger, LLC; 2022.
   Google Scholar
• Trott O, Olson AJ. AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461.
   PubMed Web of Science ®Google Scholar
• Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020;30(17):127377.
   PubMed Web of Science ®Google Scholar
• Veeramachaneni GK, Thunuguntla V, Bobbillapati J, et al. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. J Biomol Struct Dyn. 2021;39(11):4015–4025.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.e6.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhu W. Molecular docking for drug discovery and development: a widely used approach but far from perfect. Future Med Chem. 2016;8(14):1707–1710.
   PubMed Web of Science ®Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–788.
   PubMed Web of Science ®Google Scholar